Market revenue in 2023 | USD 773.9 million |
Market revenue in 2030 | USD 1,923.1 million |
Growth rate | 13.9% (CAGR from 2023 to 2030) |
Largest segment | Monoclonal antibodies |
Fastest growing segment | Monoclonal Antibodies |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Monoclonal Antibodies, Polyclonal Antibodies |
Key market players worldwide | Lonza Group Ltd, Catalent Inc, Samsung BioLogics, AGC Biologics, Boehringer Ingelheim, Charles River Laboratories International Inc, FUJIFILM Holdings Corp, Fresenius SE & Co KGaA |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antibody contract development & manufacturing organization market will help companies and investors design strategic landscapes.
Monoclonal antibodies was the largest segment with a revenue share of 67.76% in 2023. Horizon Databook has segmented the Australia antibody contract development & manufacturing organization market based on monoclonal antibodies, polyclonal antibodies covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia antibody contract development & manufacturing organization market , including forecasts for subscribers. This country databook contains high-level insights into Australia antibody contract development & manufacturing organization market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account